Schedule of Segment Reporting Information, by Segment [Table Text Block] |
Year Ended December 31, 2022
|
|
Diagnostics
|
|
|
Therapeutics
|
|
|
Corporate
|
|
|
Total
|
|
Sales revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
International
|
|
|
14,645 |
|
|
|
— |
|
|
|
— |
|
|
|
14,645 |
|
Grant and other revenue
|
|
|
51,007 |
|
|
|
— |
|
|
|
— |
|
|
|
51,007 |
|
Total revenue
|
|
|
65,652 |
|
|
|
— |
|
|
|
— |
|
|
|
65,652 |
|
Cost of revenue
|
|
|
1,941 |
|
|
|
— |
|
|
|
— |
|
|
|
1,941 |
|
Adjustments for expired and expiring inventory
|
|
|
183,006 |
|
|
|
— |
|
|
|
— |
|
|
|
183,006 |
|
Research and development expenses
|
|
|
5,501,134 |
|
|
|
468,640 |
|
|
|
— |
|
|
|
5,969,774 |
|
Selling, general and administrative expenses, excluding depreciation and amortization (1)
|
|
|
— |
|
|
|
4,530 |
|
|
|
7,861,477 |
|
|
|
7,866,007 |
|
Depreciation and amortization (2)
|
|
|
29,387 |
|
|
|
— |
|
|
|
66,432 |
|
|
|
95,819 |
|
Loss from operations (3)
|
|
|
(5,649,816 |
)
|
|
|
(473,170 |
)
|
|
|
(7,927,909 |
)
|
|
|
(14,050,895 |
)
|
Other expense, net (4)
|
|
|
— |
|
|
|
— |
|
|
|
(1,126,261 |
) |
|
|
(1,126,261 |
)
|
Net loss
|
|
|
(5,649,816 |
)
|
|
|
(473,170 |
)
|
|
|
(9,054,170 |
)
|
|
|
(15,177,156 |
)
|
Total assets, net of depreciation and amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States
|
|
$ |
610 |
|
|
$ |
— |
|
|
$ |
3,817,195 |
|
|
$ |
3,817,805 |
|
International
|
|
|
539,188 |
|
|
|
— |
|
|
|
14,613 |
|
|
|
553,801 |
|
Capital expenditures
|
|
|
54,650 |
|
|
|
— |
|
|
|
8,436 |
|
|
|
63,086 |
|
Year Ended December 31, 2021
|
|
Diagnostics
|
|
|
Therapeutics
|
|
|
Corporate
|
|
|
Total
|
|
Royalty revenue
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
License revenue
|
|
|
45,615 |
|
|
|
— |
|
|
|
— |
|
|
|
45,615 |
|
Grant and other revenue
|
|
|
485,898 |
|
|
|
— |
|
|
|
— |
|
|
|
485,898 |
|
Total revenue
|
|
|
531,513 |
|
|
|
— |
|
|
|
— |
|
|
|
531,513 |
|
Research and development expenses, excluding depreciation and amortization
|
|
|
4,488,177 |
|
|
|
653,733 |
|
|
|
— |
|
|
|
5,141,910 |
|
Selling, general and administrative expenses, excluding depreciation and amortization (1)
|
|
|
— |
|
|
|
4,438 |
|
|
|
7,368,623 |
|
|
|
7,373,061 |
|
Depreciation and amortization (2)
|
|
|
24,162 |
|
|
|
— |
|
|
|
52,792 |
|
|
|
76,954 |
|
Loss from operations (3)
|
|
|
(3,980,826 |
)
|
|
|
(658,171 |
)
|
|
|
(7,421,415 |
)
|
|
|
(12,060,412 |
)
|
Other income (4)
|
|
|
— |
|
|
|
— |
|
|
|
345,524 |
|
|
|
345,524
|
|
Provision for income taxes
|
|
|
(5,452 |
)
|
|
|
(901 |
)
|
|
|
(9,690 |
) |
|
|
(16,043 |
) |
Net loss
|
|
|
(3,986,278 |
)
|
|
|
(659,072 |
)
|
|
|
(7,085,581 |
)
|
|
|
(11,730,931 |
)
|
Total assets, net of depreciation and amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States
|
|
$ |
107,931 |
|
|
$ |
— |
|
|
$ |
6,326,031 |
|
|
$ |
6,433,962 |
|
International
|
|
|
210,281 |
|
|
|
— |
|
|
|
590 |
|
|
|
210,871 |
|
Capital expenditures
|
|
|
— |
|
|
|
— |
|
|
|
25,218 |
|
|
|
25,218 |
|
|